HOUSE_OVERSIGHT_024034.jpg
2.21 MB
Extraction Summary
1
People
4
Organizations
0
Locations
0
Events
1
Relationships
3
Quotes
Document Information
Type:
Financial report / investment performance summary
File Size:
2.21 MB
Summary
This document is page 23 of a confidential financial report (Control Number 257) marked with a House Oversight Bates stamp. It details the investment performance of New Leaf Ventures (I and II) and Sprout Funds in two sectors: Medical Devices and Tools, Diagnostics, & Infrastructure, as of March 31, 2014. The report lists aggregate costs, realized values, and internal rates of return (IRR) for these funds.
People (1)
| Name | Role | Context |
|---|---|---|
| Fund Managers | Investor |
Active investor in the medical device and tools/diagnostics sectors across New Leaf and Sprout Funds.
|
Organizations (4)
| Name | Type | Context |
|---|---|---|
| New Leaf Ventures II, L.P. |
Investment fund (2008 vintage) listed in performance tables.
|
|
| New Leaf Ventures I, L.P. |
Investment fund (2005 vintage) listed in performance tables.
|
|
| All Sprout Funds |
Investment funds (1993, 1995, 1998, 2000 vintages) listed in performance tables.
|
|
| House Oversight Committee |
Implied by Bates stamp 'HOUSE_OVERSIGHT_024034'.
|
Relationships (1)
New Leaf Ventures
→
Co-managed
→
Sprout Funds
Both are managed by the same 'Fund Managers' and presented together in performance summaries.
Key Quotes (3)
"Combined, the Fund Managers have invested $371 million in 29 medical device companies, and have gross realizations of $394 million and a 1.82x gross realized Multiple and 9.4% gross realized IRR."Source
HOUSE_OVERSIGHT_024034.jpg
Quote #1
"Combined, the Fund Managers have invested in 17 companies, for a total $221 million in cost."Source
HOUSE_OVERSIGHT_024034.jpg
Quote #2
"CONTROL NUMBER 257 - CONFIDENTIAL"Source
HOUSE_OVERSIGHT_024034.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document